{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:27:52Z","timestamp":1791912472892,"version":"4.3.4"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00415-022-11222-8","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T03:39:21Z","timestamp":1655350761000},"page":"6152-6154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report"],"prefix":"10.1007","volume":"269","author":[{"given":"Camilla M. M.","family":"Strano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Sorrenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri M.","family":"Falzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"issue":"26","key":"11222_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis Longo DL, editor. N Engl J Med 375(26):2570\u20132581","journal-title":"N Engl J Med"},{"issue":"4","key":"11222_CR2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.tmrv.2019.09.004","volume":"33","author":"CJ Patriquin","year":"2019","unstructured":"Patriquin CJ, Kuo KHM (2019) Eculizumab and beyond: the past, present, and future of complement therapeutics. Transfus Med Rev 33(4):256\u2013265","journal-title":"Transfus Med Rev"},{"key":"11222_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/brb3.2242","volume":"11","author":"W Cheng","year":"2021","unstructured":"Cheng W, Sun T, Liu C, Zhou Z, Duan J, Zhao Y et al (2021) A systematic review of myasthenia gravis complicated with myocarditis. Brain Behav [Internet]. 11:8. https:\/\/doi.org\/10.1002\/brb3.2242","journal-title":"Brain Behav [Internet]."},{"issue":"7","key":"11222_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40265-020-01297-w","volume":"80","author":"JE Frampton","year":"2020","unstructured":"Frampton JE (2020) Eculizumab: a review in neuromyelitis optica spectrum disorder. Drugs 80(7):719\u2013727","journal-title":"Drugs"},{"issue":"12","key":"11222_CR5","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J, Brodsky RA, Soci\u00e9 G, Muus P et al (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355(12):1233\u20131243","journal-title":"N Engl J Med"},{"issue":"7","key":"11222_CR6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40262-019-00742-8","volume":"58","author":"KL Wijnsma","year":"2019","unstructured":"Wijnsma KL, ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina-Elena B et al (2019) Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab. Clin Pharmacokinet 58(7):859\u2013874","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"11222_CR7","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.1002\/mus.26124","volume":"58","author":"CJJ Yeo","year":"2018","unstructured":"Yeo CJJ, Pleitez MY (2018) Eculizumab in refractory myasthenic crisis. Muscle Nerve 58(2):E13\u2013E15","journal-title":"Muscle Nerve"},{"key":"11222_CR8","doi-asserted-by":"publisher","first-page":"175628642090420","DOI":"10.1177\/1756286420904207","volume":"13","author":"M Oyama","year":"2020","unstructured":"Oyama M, Okada K, Masuda M, Shimizu Y, Yokoyama K, Uzawa A et al (2020) Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis. Ther Adv Neurol Disord 13:175628642090420","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"11222_CR9","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1007\/s00415-021-10428-6","volume":"268","author":"U Hofstadt-van Oy","year":"2021","unstructured":"Hofstadt-van Oy U, Stankovic S, Kelbel C, Oswald D, Larrosa-Lombardi S, Barchfeld T et al (2021) Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19. J Neurol 268(9):3125\u20133128","journal-title":"J Neurol"},{"issue":"2","key":"11222_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mus.27326","volume":"64","author":"U Usman","year":"2021","unstructured":"Usman U, Chrisman C, Houston D, Haws CC, Wang A, Muley S (2021) The use of eculizumab in ventilator-dependent myasthenia gravis patients. Muscle Nerve 64(2):212\u2013215","journal-title":"Muscle Nerve"},{"key":"11222_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01181-3","author":"F Vanoli","year":"2022","unstructured":"Vanoli F, Mantegazza R (2022) Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management. Neurotherapeutics. https:\/\/doi.org\/10.1007\/s13311-022-01181-3","journal-title":"Neurotherapeutics"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11222-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11222-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11222-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T12:04:30Z","timestamp":1665489870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11222-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["11222"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11222-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"assertion":[{"value":"14 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CMM Strano, B Sorrenti, L Bosco, YM Falzone, and R Fazio report no disclosures.\u00a0Prof. Filippi is Editor-in-Chief of the <i>Journal of Neurology<\/i>, Associate Editor of <i>Human Brain Mapping<\/i>, Associate Editor of <i>Radiology<\/i>, and Associate Editor of <i>Neurological Sciences<\/i>; received compensation for consulting services and\/or speaking activities from Alexion, Almirall, Bayer, Biogen, Celgene, Eli Lilly, Genzyme, Merck-Serono, Neopharmed Gentili, Novartis, Roche, Sanofi, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The patient gave explicit informed consent to report his clinical case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}